Phase 3 First Patient Dosed

Innovate Biopharmaceuticals dosed the first patient in the their Phase 3 trial of Larazotide acetate a few days ago. The drug is designed to alleviate symptoms of accidental gluten exposure, however it is unclear if the drug will protect against the intestinal damage due to gluten exposure. The phase 3 trial will need over 600 volunteers and is expected to be completed at the end of 2021.

Review the study and decide if it is something you can do to help move science forward!!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s